Welcome to our dedicated page for CYAD news (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on CYAD stock.
Celyad Oncology SA (CYAD) is a biotechnology company headquartered in Mont‑Saint‑Guibert, Belgium, with shares admitted to trading on Euronext. Its regulatory news flow provides detailed insight into the company’s strategic focus on managing and licensing its intellectual property portfolio, including proprietary technology platforms, as well as its capital structure and major shareholdings.
News about Celyad Oncology frequently covers decisions that affect its operational profile and financial position. For example, the company has announced the discontinuation of its research and development activities and a significant reduction in its R&D workforce due to limited cash resources, stating that it will concentrate on the management and licensing of its intellectual property portfolio. Other releases describe the divestiture of its research facility’s equipment and office furniture under an asset purchase agreement, which management expects to extend the company’s cash runway.
Investors following CYAD news can also track financing transactions and ownership changes. The company has reported a private placement financing with CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group, and has issued multiple transparency notifications detailing when this shareholder has crossed voting‑rights thresholds. In addition, Celyad Oncology regularly publishes updates on the total number of shares and voting rights, including the impact of double voting rights on certain registered shares.
This news page is useful for readers who want to monitor regulatory announcements on Celyad Oncology’s strategic decisions, capital increases, asset sales, major shareholdings and voting‑rights structure. By reviewing these updates, users can follow how the company’s focus on intellectual property, its financing arrangements and its ownership profile evolve over time.
Celyad Oncology has announced positive initial results from the Phase 1 IMMUNICY-1 trial of its anti-BCMA CAR T candidate, CYAD-211, focused on relapsed/refractory multiple myeloma. The first dose-level cohort showed no Grade ≥ 3 treatment-related adverse events or Graft-versus-Host disease. Notably, a confirmed partial response was observed in one patient receiving a low dose of 30x106 cells. The trial aims to assess the safety and efficacy of CYAD-211, utilizing a non-gene editing technology that minimizes safety risks. Results will be presented at the upcoming EHA Virtual Congress 2021.
Celyad Oncology has provided updates on its clinical trials and financial results for Q1 2021. The Phase 1 IMMUNICY-1 trial for CYAD-211, an allogeneic CAR T candidate, is ongoing with no safety issues reported. Additionally, the alloSHRINK trial for CYAD-101 is progressing, with preliminary data expected mid-2021. The company has appointed new key personnel and entered a $40 million equity purchase agreement with Lincoln Park Capital. As of March 31, 2021, Celyad had €12.2 million in cash, enough to fund operations until mid-2022.
Celyad Oncology (Euronext & Nasdaq: CYAD) announced on May 3, 2021, that Tolefi SA holds 2,295,701 shares with a double voting right, exceeding the 25% ownership threshold. This notification highlights Tolefi's increased influence in corporate decisions. Celyad Oncology is focused on developing CAR T cell therapies for cancer, including a pipeline of allogeneic and autologous candidates. The company has received funding from the Walloon Region in Belgium to advance its research initiatives.
Celyad Oncology SA announced a double voting right for Tolefi SA’s shares effective May 3, 2021, increasing the total number of voting rights to 17,373,181. The company's total share capital amounts to €52,211,200.33, consisting of 12,637,131 shares with single voting rights and 2,368,025 shares with double voting rights. The disclosure is in line with the Belgian law regarding major participations in listed companies.
Celyad Oncology has completed two capital increases, issuing 300,000 new shares to Lincoln Park Capital Fund, LLC, increasing its share capital to 52,211,200.33 EUR and total shares to 15,005,156. The company reported 14,932,832 shares with single voting rights and 72,324 with double voting rights. Total voting rights reached 15,077,480, with a total of 1,802,756 warrants outstanding. These actions comply with Belgian regulations on major participations in publicly traded firms.
Celyad Oncology (Euronext & Nasdaq: CYAD) announced the appointment of Dr. Charles Morris as Chief Medical Officer, aiming to enhance its medical and clinical strategies. Dr. Morris, with over 20 years of experience in oncology drug development, previously held significant roles at Radius Health and Cephalon, contributing to multiple drug approvals. His expertise is expected to be pivotal during a crucial year for the company, which anticipates several important data readouts regarding its allogeneic CAR T therapies.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced its participation in several upcoming conferences in April 2021, focusing on CAR T therapies for cancer. Key events include the Cell & Gene Meeting on the Mediterranean (April 6-9), where CEO Filippo Petti will present, and the 2021 Virtual Wells Fargo Biotech Corporate Access Day on April 8. The company is dedicated to developing innovative CAR T therapies for hematological malignancies and solid tumors, supported by funding from the Walloon Region of Belgium.
Celyad Oncology (CYAD) announced a capital increase of 200,000 new shares to Lincoln Park Capital Fund on March 29, 2021. The total share capital now amounts to 50,123,200.33 EUR, represented by 14,405,156 shares. Following this transaction, the total number of shares with single voting rights stands at 14,332,832, while double voting shares total 72,324.
The dilutive impact of this share issuance increases the total diluted share count to 16,139,595, including warrants. This adjustment complies with Belgian regulations regarding major participations.
Celyad Oncology SA (CYAD) reported no safety concerns in the Phase 1 IMMUNICY-1 trial for its lead shRNA-based CAR T candidate, CYAD-211, aimed at treating relapsed/refractory multiple myeloma. Enrollment in the second dose cohort has begun, with additional data anticipated in Q2 2021. The company is also progressing with its alloSHRINK trial for CYAD-101 in advanced metastatic colorectal cancer, with preliminary data expected soon. As of December 31, 2020, Celyad had a cash position of €17.2 million ($21.2 million) and entered a $40 million equity purchase agreement to support operations.
Celyad Oncology will announce its full year 2020 financial results on March 24, 2021. A conference call for discussion will take place on March 25 at 1 p.m. CET / 8 a.m. ET. The company focuses on developing chimeric antigen receptor T cell (CAR T) therapies for cancer, including allogeneic and autologous candidates targeting hematological malignancies and solid tumors. Celyad has received funding from the Walloon Region to support its CAR T programs. The company warns that known and unknown risks may impact its financial condition and business outlook.